German biotech company Repairon GmbH announced the completion of a Series A round of financing that will enable further clinical development of its groundbreaking regenerative heart failure therapy.

Symbio Bioculinary does not concern submission combat or landscaping businesses, it upcycles food waste to tackle the over 30 ...

A Rockville clinical-stage biotech has closed a $50 million Series B round to advance its potential treatments for cancer and ...

SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced the appointments of two accomplished scientific executives to its leadership team to support the continued ...

Gilead looks attractive again. Its innovative edge and new crop of medications are performing well across multiple ...

Anavex Life Sciences (NASDAQ:AVXL) traded higher in the premarket on Thursday after the New York-based biotech said that a mid-stage trial for its experimental antipsychotic ANAVEX 3-71 reached the ...

The company is working on T cell engagers and other multifunctional antibodies, led by a prospect it believes might be ...

French biotech EG 427 has had success with its urinary incontinence DNA therapy, EG110A, showing a more than 80% reduction in ...

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter: Agios ...

A drug developer planning to seek FDA approval for its first drug before the end of the year has signed a 32,000-square-foot ...

Join us for Bisnow's 2025 New York Life Sciences Conference where top developers and city officials will discuss attracting ...